“NorthStar has quickly achieved several key milestones in advancing our strategically planned RadioGenix System roll-out,” said George P. Messina, Chairman and CEO of NorthStar. “First, the FDA approval of our Beloit manufacturing facility enables us to scale up production and expand capacity to meet anticipated customer demand. The approval came well in advance of the anticipated FDA action date. Second, we are also very pleased to announce that the commercial launch of the RadioGenix System has commenced, with the first contract signed and the first installation scheduled at a customer site. This important event marks another milestone in NorthStar’s commitment to provide the United States healthcare system with a reliable, domestic non-uranium based Mo-99 supply for production of the important medical diagnostic imaging radioisotope, technetium-99m. We anticipate shipping additional RadioGenix Systems as potential customers receive licensing amendments for their sites, and look forward to sharing our progress.” Read the full story here.
- WisBusiness: Legislature passes bills related to startup funding, oversightNovember 18, 2019
- WisconsinINNO: Meet the 3 Startups That Took Home Trophies at Wisconsin Tech Council’s Pitch OlympicsNovember 18, 2019
- Bipartisan bills tied to investing, UW startups on way to governor after passing LegislatureNovember 14, 2019
- InsideWis: Are Janesville and Monona, Wis., the center of the fusion world? They may well beNovember 14, 2019
- It’s a wrap! 2019 Wisconsin Early Stage SymposiumNovember 12, 2019